Giuseppe Andò: P2Y12 Inhibition in Diabetes – A Personalized Approach
Giuseppe Andò, Head of the Cardiology Department at Papardo University Hospital, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Cardiovascular Diabetology, adding:
“New publication in Cardiovascular Diabetology!
P2Y12 inhibition in diabetes across the acute-to-chronic coronary syndrome continuum: toward a personalized antiplatelet strategy.
Diabetes increases thrombotic risk, but antiplatelet intensity should not be one-size-fits-all.
We review the evidence across ACS to CCS and discuss how ischemic/bleeding risk, PCI complexity, comorbidities and other patient characteristics should guide P2Y12-based therapy.”
Title: P2Y12 inhibition in diabetes across the acute-to-chronic coronary syndrome continuum: toward a personalized antiplatelet strategy
Authors: Lucio Giuseppe Granata, Marcello Marchetta, Pierre Sabouret, Andrea Muscarà, Giuseppina Tiziana Russo, Giuseppe Andò

Stay updated with Hemostasis Today.
-
Nov 16, 2026, 10:08Abdul Mannan: When Normal Blood Counts Hide Iron Deficiency
-
Nov 16, 2026, 09:47Ankit Kumar: A Memorable Experience at Haematocon 2026
-
Nov 15, 2026, 23:44Pablo César Spada: Prevention of Venous Thromboembolism After Total Hip or Knee Replacement
-
Nov 15, 2026, 23:30Eshal Amir: Factor XI Inhibitors in AFib and Aortic Mortality Trends
-
Nov 15, 2026, 23:19Hamza Bashir: Adding Endovascular Therapy to Anticoagulation Cuts Moderate-to-Severe PTS in Half
-
Nov 15, 2026, 23:06Lanre Tunji-Ajayi: 2 Days of Deliberative Dialogue Hosted by the Network of Rare Blood Disorder Organizations
-
Nov 15, 2026, 23:00Fanny Delettre: Looking Back at Volunteer Blood Donor Friends Day
-
Nov 15, 2026, 20:56Victoria Adedoyin Adisa-Thomas: What I Learned About SCD During My Genetic Counselling Rotation
-
Nov 15, 2026, 20:55Martin Holst Lange: One Step Closer to a Potential New Treatment for Sickle Cell Disease